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Suppression of Staphylococcus 
aureus biofilm formation and 
virulence by a benzimidazole 
derivative, UM-C162
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Staphylococcus aureus is a major cause of nosocomial infections and secretes a diverse spectrum 
of virulence determinants as well as forms biofilm. The emergence of antibiotic-resistant S. aureus 
highlights the need for alternative forms of therapeutics other than conventional antibiotics. One route 
to meet this need is screening small molecule derivatives for potential anti-infective activity. Using 
a previously optimized C. elegans – S. aureus small molecule screen, we identified a benzimidazole 
derivative, UM-C162, which rescued nematodes from a S. aureus infection. UM-C162 prevented 
the formation of biofilm in a dose-dependent manner without interfering with bacterial viability. 
To examine the effect of UM-C162 on the expression of S. aureus virulence genes, a genome-wide 
transcriptome analysis was performed on UM-C162-treated pathogen. Our data indicated that 
the genes associated with biofilm formation, particularly those involved in bacterial attachment, 
were suppressed in UM-C162-treated bacteria. Additionally, a set of genes encoding vital S. aureus 
virulence factors were also down-regulated in the presence of UM-C162. Further biochemical analysis 
validated that UM-C162-mediated disruption of S. aureus hemolysins, proteases and clumping factors 
production. Collectively, our findings propose that UM-C162 is a promising compound that can be 
further developed as an anti-virulence agent to control S. aureus infections.
Staphylococcus aureus is a clinical pathogen that causes both human and animal infections, ranging from mild 
superficial infections to toxin-associated diseases and severe life-threatening invasive infections1. S. aureus is 
acknowledged as a key agent implicated in nosocomial infections resulting in significant morbidity and mortality 
among hospitalized patients. This is in part due to its ability to adhere to the surface of indwelling medical devices 
and develop biofilm, a multilayered structure comprising of bacterial communities embedded within the extra-
cellular hydrated polymeric matrix2.
To survive the onslaught of the host immune response and establish an infection, S. aureus expresses a com-
prehensive array of virulence determinants, including extracellular toxins (e.g. hemolysins, leukotoxins and 
enterotoxins), enzymes (e.g. proteases and coagulases) and surface proteins (e.g. clumping factors, adhesins and 
S. aureus surface proteins)3. The secretion of these virulence factors and formation of biofilm are controlled by a 
sophisticated network of virulence regulators such as the agr, sarA, saeR/S and arlRS4. The diversity of S. aureus 
virulence factors along with the ability to form disease-associated biofilm presents a challenge to the host immune 
defence to fully eradicate the bacteria whilst rendering the bacteria highly tolerant to antibiotics, leading to per-
sistent chronic infections2.
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The growing frequency of antibiotic-resistant S. aureus strains as exemplified by methicillin-resistant S. aureus 
(MRSA) is a serious threat to the community and highlights a pressing need for alternative therapies that impose 
minimum selection pressure upon the bacteria. The cumulative understanding of bacterial virulence and patho-
genesis opens up new perspectives for developing novel therapies by attenuating bacterial virulence and/or bio-
film as alternative treatment options for bacterial infections5–8. Recent studies have focused on development 
of small molecules and phytochemicals to inhibit the formation of biofilm and/or other virulence factors in S. 
aureus9–12. As most virulence traits are non-essential for bacterial survival, these strategies hold great promise 
as effective means to control bacterial infections with less probability for selection of resistant populations13,14.
Benzimidazole is structurally analogous to naturally occurring nucleotides, making it a key intermediate in the 
synthesis of new chemical entities of biological interest. The benzimidazole class of compounds are known to pos-
sess an extensive range of pharmacological activities such as anti-malarial, anti-cancer and antioxidative effects15. 
In light of the notable therapeutic properties of the benzimidazole scaffold, we performed an in vivo screen on 
a collection of 35 benzimidazole derivatives for potential anti-infective effects using a previously established C. 
elegans – S. aureus anti-infective screen16. In an anti-biofilm assay, several compounds reduced the formation of 
biofilm without inhibiting the growth of S. aureus and the most potent derivative, 2-(4′-((3-acetamidobenzyl)
oxy)-[1,1′-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (referred to as UM-C162 henceforth) 
was selected for further analysis. Transcriptome profiling was also performed on UM-C162-treated S. aureus to 
identify the bacterial virulence factors targeted by UM-C162.
Results
Benzimidazole derivatives exhibit anti-infective and anti-biofilm activities. In the current study, 
we extended the utility of a previously optimized C. elegans – S. aureus anti-infective screen16 to explore the 
potential anti-infective property of a series of benzimidazole compounds. The premise of the screen was that 
the addition of individual compounds that are able to rescue the nematodes from a lethal S. aureus infection 
are deemed to exhibit potential anti-infective effects. We screened 35 benzimidazole derivatives (Table S1) and 
observed that 12 compounds increased the survival of infected worms to > 70% at a point when ~80% of the 
untreated worms succumbed to the infection (Fig. 1a). The 12 positive hits are compounds UM-C41, UM-C42, 
UM-C43, UM-C44, UM-C48, UM-C49, UM-C162, UM-C164, UM-C188, UM-C189, UM-C201 and UM-C203. 
All positive hits (at 100 µM) enhanced the survival of S. aureus infected-worms by 3 to 4-fold relative to the 
untreated control after 96 hours post-infection. On the other hand, we also noticed a small number of compounds 
(namely UM-C50, UM-C73, UM-C74 and UM-C204) that accelerated the killing of S. aureus-infected worms, 
resulting in a lower survival of nematodes (<10%) as compared to the untreated infected worms (~20%) (Fig. 1a). 
To address the possible toxic effect of these four compounds on the host, we repeated the assay on worms exposed 
to heat-killed Escherichia coli OP50 in the presence of these compounds. As expected, the survival of the worms 
decreased significantly as early as 48 hours post-exposure (Fig. S1), indicating that these compounds are indeed 
toxic to the host.
Previously, Begun et al. reported that S. aureus that overexpressed the icaADBC locus and constitutively pro-
duced excess biofilm exopolysaccharide, killed worms significantly faster as compared to a strain that produced 
less biofilm, suggesting that staphylococcal biofilm is a virulence mechanism employed by the bacteria that con-
tributes to death of the infected host17. In another study, a benzimidazole-derived molecule (ABC-1) was iden-
tified as a broad-spectrum biofilm inhibitor towards both Gram-positive and Gram-negative bacteria18. ABC-1 
suppresses S. aureus protein A (SpA) expression and prevents the accumulation of polysaccharide intercellular 
adhesin (PIA)19. Therefore, it is possible that some of the hits identified from the C. elegans anti-infective screen 
may regulate the production of biofilm by S. aureus, thereby extending the survival of infected nematodes. To 
examine the potential anti-biofilm property of the hits, bacteria were cultured in the presence of the individ-
ual compounds and biofilm formation was screened using the 96-well crystal violet biofilm assay20. Following 
24 hours incubation under static conditions, three of the 12 hits (UM-C42, UM-C162 and UM-C164) dramat-
ically inhibited S. aureus biofilm development by > 70% (p < 0.01). The most pronounced anti-biofilm activity 
was observed for UM-C162 (Fig. 1b). UM-C42, UM-C162 and UM-C164 at a concentration of 100 µM were 
able to inhibit biofilm formation to 41 ± 2.4%, 19 ± 1.4% and 32 ± 0.8% of the untreated bacteria, respectively. 
The molecular structures of these compounds are presented in Fig. 1c. The ability of UM-C42, UM-C162 and 
UM-C164 to diminish the biofilm-forming capability of S. aureus suggests that these compounds rescued the 
nematodes from infection via attenuation of this bacterial virulence factor. As compound UM-C162 was most 
effective in preventing S. aureus biofilm formation, we further assessed the effect of this compound on S. aureus 
biofilm production across a series of lower concentrations. The results showed that UM-C162 reduced S. aureus 
biofilm formation in a concentration-dependent manner after treatment for 24 hours, where supplementation of 
UM-C162 from 0.78 µM to 100 µM was able to reduce biofilm formation by 8.9% to 68% (Fig. 1d). Based on these 
data, inhibition of >50% biofilm formation was achieved with 6.25 µM of UM-C162. We thus selected 6.25 µM as 
the lowest working concentration for the rest of the assays.
UM-C162 disrupts biofilm formation without affecting S. aureus growth. To further character-
ize the effect of UM-C162 on S. aureus biofilm, S. aureus was supplemented with 6.25 µM, 12.5 µM and 25 µM 
UM-C162 and biofilm was allowed to develop on the surface of glass slides in a multi-well plate. The morphology 
of UM-C162-treated and untreated S. aureus biofilm architecture formed on the glass slides following 24 hours 
incubation was visualized using scanning electron microscopy (SEM). Under 1000x magnification, SEM analysis 
revealed a thick, dense and fully established biofilm consisting of multi-layered bacterial cells (Fig. 2a). Upon 
treatment with UM-C162, biofilm production was disrupted and a negligible biofilm mass was detected on the 
glass slide. The bacteria appeared as a monolayer of dispersed cells scattered on the surface (Fig. 2a). At higher 
magnification (5000x), untreated S. aureus appeared as large aggregates of cells in overlapped layers (Fig. 2b). In 
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contrast, bacteria treated with 6.25 µM of UM-C162 presented as a uniform layer of cells with negligible clump-
ing (Fig. 2b). A similar observation was noted upon supplementation with higher concentrations of UM-C162 
(Fig. S2). These images validate the data from the crystal-violet biofilm assay.
We further evaluated the biofilm inhibitory effect and biofilm eradication activity of UM-C162 against two 
different strains of S. aureus (S. aureus ATCC25923 and a MRSA clinical strain) using an artificial dermis wound 
model21,22. To assess the biofilm inhibitory activity, the dermis was supplemented with UM-C162 before the for-
mation of biofilm. On the other hand, in the biofilm eradication assay, we exposed the 24-hour old biofilm to 
UM-C162 for 24 hours before harvesting the biofilm cells to enumerate bacterial colony forming units (CFU). In 
the inhibition assay, formation of biofilm was noted in the untreated infected wound whilst no visually detect-
able biofilm was observed in artificial dermis wounds treated with 50, 100 and 200 µM of UM-C162 for both S. 
aureus (Fig. S3a) and MRSA (Fig. S3b). This concentration range was selected based on a preliminary screen 
across a series of concentrations using the similar artificial dermis model. For the inhibition assay, in the absence 
of UM-C162, the bacterial load was 3.2 × 106 CFU for S. aureus and 2.6 × 106 for MRSA. Upon treatment with 
UM-C162, we observed a significant reduction (p < 0.001) in the number of S. aureus harvested from the arti-
ficial dermis i.e. 3.2 × 105 (50 µM), 2.7 × 105 (100 µM) and 1.0 × 105 (200 µM) whilst for MRSA, the number of 
Figure 1. Benzimidazole derivatives rescued C. elegans from a S. aureus infection and altered S. aureus biofilm 
formation. (a) Survival of S. aureus-infected nematodes upon treatment with individual benzimidazole 
compounds (100 µM). Results are shown as mean ± SD from a single replicate of two independent screens. 
The straight line shows the survival of untreated worms while the dashed line demarcates the positive hits. 
Compounds that promoted the survival of infected worms to > 70% were considered as positive in the screen. 
(b) Effect of benzimidazole compounds (100 µM) towards S. aureus biofilm formation. (c) Molecular structures 
of compounds UM-C42, UM-C162 and UM-C164 that demonstrated significant anti-biofilm activity. (d) 
Dose-dependent anti-biofilm effect of compound UM-C162. The graphs in (b) and (d) depict the percentage 
of biofilm formation after 24 hours incubation of S. aureus in the presence and absence of compounds. Three 
independent experiments were conducted. Error bars indicate SEM. Images of representative wells from the 
crystal-violet biofilm assay are shown. (**) denotes significant difference between untreated and compound-
treated bacteria (p < 0.01).
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bacteria was 1.7 × 105 (50 µM), 6.5 × 104 (100 µM) and 4.0 × 104 (200 µM) (Fig. 3a). Similarly, in the eradication 
assay, UM-C162-treated wounds demonstrated a substantial reduction in bacterial loads for S. aureus and MRSA 
(p < 0.001) (Fig. 3b). Bacterial loads recovered from the untreated 24-hour old biofilm were 2.7 × 108 CFU for 
S. aureus and 4.4 × 108 for MRSA. Bacterial CFU were 1.3 × 107, 2.1 × 107, 1.4 × 106 for S. aureus and 1.3 × 107, 
8.6 × 106 and 3.2 × 105 for MRSA after exposure to UM-C162 at 50, 100 and 200 µM respectively, suggesting that 
UM-C162 might be able to eradicate the pre-formed biofilms or prevent further biofilm formation in an infected 
wound.
S. aureus susceptibility towards UM-C162 was tested across a range of concentrations using the broth microdi-
lution MIC test. Gentamicin was tested in parallel as the positive control and was antimicrobial towards S. aureus 
with an MIC of < 30 µg/mL (Fig. S4). On the other hand, S. aureus supplemented with different concentrations 
of UM-C162 appeared turbid after an overnight incubation, indicating that over a dose of 0.05 µM to 200 µM, 
UM-C162 did not inhibit S. aureus growth (Fig. S4). To confirm the MIC data, the effect of UM-C162 on S. aureus 
growth was evaluated by monitoring the absorbance at OD600nm of batch cultures. S. aureus showed a similar 
growth rate in the presence and absence of UM-C162 (Fig. 4a), confirming that UM-C162 at concentrations 
ranging from 6.25 µM to 25 µM did not interfere with S. aureus growth. These findings also propose that the atten-
uation of S. aureus virulence by UM-C162 is mainly due to the compound’s ability to retard biofilm production 
and not to its antimicrobial activity against planktonic cells.
To further assess the protective role of UM-C162 towards the host in vivo, the lifespan of infected nematodes 
in the presence and absence of UM-C162 was monitored in a survival assay with additional time points and a 
greater number of worms. S. aureus killed the nematodes with a mean-time-to-death (TDmean) of 114.5 ± 3.7 hours 
(4.7 days) (Fig. 4b). Complete killing of all nematodes was achieved in 7–8 days. Upon treatment with 6.25 µM, 
12.5 µM and 25 µM of UM-C162, the TDmean of S. aureus-infected worms was markedly improved to 207.1 ± 5.5, 
244.5 ± 7.0 and 290.2 ± 7.8 hours, respectively (p < 0.0001) (Fig. 4b). Hence, the killing kinetics of infected worms 
was significantly delayed in a concentration-dependent manner for worms treated with UM-C162.
We then asked if UM-C162 is toxic towards a multicellular eukaryotic organism. To test this, we exposed the 
worms to various concentrations of UM-C162 in the absence of infection and lifespan of the worms was mon-
itored. No significant difference was observed between the lifespan of UM-C162-treated and untreated worms, 
where both survived for ~17 days at 25 °C (Fig. 4c), ruling out the possibility that the compound could cause 
adverse effects onto the host. Moreover, the compound did not further extend the basal lifespan of nematodes, 
implying that the increased survival of nematodes infected by S. aureus is unlikely to be an outcome of any 
lifespan extending property of UM-C162.
Figure 2. Scanning electron microscopy micrographs of the S. aureus biofilm structure. (a) Biofilm formation 
by untreated (0 µM) and UM-C162-treated S. aureus (6.25 µM) following 24 hours incubation (1000x 
magnification). (b) Bacterial cells cluster in untreated S. aureus (0 µM) and the absence of cell aggregates in UM-
C162-treated bacteria (6.25 µM) under 5000x magnification.
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S. aureus global transcriptional profile in response to treatment with UM-C162. The expression 
of S. aureus virulence traits and components required for biofilm formation is tightly regulated by a compli-
cated coordination of two-component systems and various transcriptional regulators4. Therefore, we postulated 
that a compound that can alter the formation of biofilm might also be able to reduce bacterial virulence. To 
probe the transcriptional changes of S. aureus in response to UM-C162, total RNA was isolated from the bacteria 
after overnight incubation in the presence of 6.25 µM UM-C162. Three independent microarray experiments 
were conducted to compare the gene expression profile of UM-C162-treated and untreated S. aureus. GeneChip 
analysis revealed a substantial number of genes (456) that were significantly modulated by UM-C162 (fold 
change ≤ −2 and ≥ 2, p < 0.05). Of these, 235 genes were up-regulated whilst 221 genes were down-regulated 
in UM-C162-treated S. aureus (Fig. 5a,b). A complete list of all genes differentially expressed by UM-C162 is 
available in Table S2. The microarray data is deposited in the NCBI Gene Expression Omnibus (GEO) (Accession 
number: GSE84485).
We validated the microarray derived expression data of a subset of genes by quantitative real-time PCR 
(qRT-PCR). The relative expression levels of five up-regulated genes and seven down-regulated genes were 
compared using RNA extracted from three independent bacterial cultures. A strong positive correlation was 
observed for the qRT-PCR and microarray derived data for all twelve genes tested, albeit with different magni-
tudes (Fig. 5c).
The differentially expressed genes were classified into their respective functional groups using clusters of ort-
hologous groups (COGs) designations. The distribution of UM-C162-modulated genes and their biological roles 
according to COGs classification is shown in Fig. 6. Of note, a majority of the genes were grouped as hypothetical 
proteins (32%), general function prediction only (9%) and genes with function unknown (8.7%). By comparing 
the number of up-regulated and down-regulated genes in each functional group, we noted that the group of 
translation-, ribosomal structure- and biogenesis-encoding genes contained a higher number of up-regulated 
genes (34) and only 3 down-regulated genes whilst genes involved in cell wall/membrane/envelope biogenesis 
and replication, recombination and repair were mainly down-regulated (12 and 13 genes, respectively) and only 2 
Figure 3. UM-C162 displays anti-biofilm activity in an artificial dermis wound model. Number of S. aureus 
and MRSA CFU recovered from biofilm formed on artificial dermis after exposure to various concentrations 
of UM-C162 for 24 hours in (a) biofilm inhibition and (b) biofilm eradication assays. Data represent the 
mean ± SD of two biological replicates. (**) denotes significant difference between untreated and compound-
treated bacteria (p < 0.001).
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or 5 up-regulated genes, respectively (Fig. 6). Other UM-C162-regulated genes were generally classified as genes 
involved in amino acid transport and metabolism, carbohydrate transport and metabolism, energy production 
and conversion, and transcription.
Further gene function enrichment analysis on the induced genes based on Gene Ontology (GO) Term iden-
tified significant enrichment (p < 0.0001) of genes involved in translation. In addition, KEGG pathway analysis 
showed enrichment of prokaryotic-type ATP-binding cassette (ABC) transporter/permease proteins (p < 0.001). 
On the other hand, the genes repressed by UM-C162 were mainly involved in cell wall/external encapsulat-
ing structure (p < 0.0001), virulence/pathogenesis (p < 0.0001) and response to stress/DNA repair (p < 0.01) 
(Table 1).
Genes encoding the ABC transporters SAOUHSC_01311 and SAOUHSC_01312 were among the most highly 
induced genes, with an induction magnitude of 294.62 and 125.66 fold, respectively (Table S2). ABC transporters 
are transmembrane proteins with diverse roles in cellular function, including the translocation of various sub-
stances (amino acids, metabolic products, lipids and drug molecules) across membranes23. Hence, the observed 
induction of ABC transporter genes may be associated with the active transport of UM-C162 molecules in and 
out of the bacterial cells. Exposure to UM-C162 also resulted in an up-regulation of ribosomal protein subunits 
encoded by rps, rpl and rpm (2 to 4-fold induction) (Table S2). Genes encoding ABC transporters and ribosomal 
proteins were also up-regulated in S. aureus exposed to ortho-phenylphenol, a phenolic compound with known 
antimicrobial properties24.
UM-C162 represses the expression of biofilm-associated genes in S. aureus. To decipher the 
molecular mechanism underlying the ability of UM-C162 to inhibit S. aureus biofilm, we compared our list of dif-
ferentially expressed genes to reported S. aureus biofilm-related genes25–27. Generally, many biofilm-related genes 
were indeed suppressed following S. aureus exposure to UM-C162 (Table 2). Specifically, genes encoding proteins 
that mediate cell adhesion and bacterial attachment (SAOUHSC_02690, clfA, clfB, sdrC, sdrH, eno and arlS) 
were among the major group of genes suppressed by UM-C162. The clumping factors (Clf) and serine-aspartate 
repeat-containing proteins (Sdr) are typical S. aureus microbial surface component-recognizing adhesive matrix 
molecules (MSCRAMMs) that promote adherence of bacteria to a substratum and induce staphylococcal biofilm 
formation28. Clumping factors enable the binding of bacterial cells to fibrinogen and have been identified as an 
important virulence determinant in various infection models29,30. Enolase (eno) mediates S. aureus pathogenesis 
by adhering to laminin-containing extracellular matrix31 and has also been shown to enhance bacterial invasive-
ness and metastasis to secondary sites of infection in other pathogens32. ArlS is a member of the two-component 
system ArlS-ArlR involved in the regulation of S. aureus adhesion, autolysis, multidrug resistance and production 
of virulence factors33. An arlS mutant exhibited increased biofilm production when cultured on a polystyrene 
surface; however, intercellular adhesion and cell aggregation properties of this mutant were impaired34. The abro-
gation of arlS promoted peptidoglycan hydrolase activity leading to cell autolysis. Thus, it was proposed that the 
arl system might be required for cell growth and division as well as bacterial adherence to polymer surfaces34. In 
general, the development of biofilm involves three key steps which are initial attachment, proliferation and mat-
uration of biofilm, followed by detachment or dispersal of cells and dissemination of the bacteria35. Collectively, 
our findings propose that UM-C162 most likely blocks the primary attachment/adhesion during biofilm forma-
tion, preventing further development of the biofilm.
In addition to genes encoding cell adhesion and attachment, treatment of S. aureus with UM-C162 also led 
to a down-regulation of genes encoding for capsular polysaccharide (SAOUHSC_00114, capF, capL and capA), 
teichoic acid (SAOUHSC_00974 and SAOUHSC_00643) and peptidoglycan (SAOUHSC_01987) biosynthe-
sis as well as Gram positive cocci surface proteins (Table 2). Among them, SAOUHSC_00974 encoding a poly 
(glycerol-phosphate) alpha-glucosyltransferase for teichoic acid biosynthesis was suppressed up to 25.4-fold. 
Polysaccharide capsule, cell wall teichoic acid, peptidoglycan and surface proteins are all essential constituents of 
Figure 4. UM-C162 improves the lifespan of S. aureus-infected nematodes without affecting bacterial growth. 
(a) UM-C162 does not inhibit the growth of S. aureus in the presence of 6.25 µM, 12.5 µM and 25 µM UM-
C162. (b) Survival curves of S. aureus-infected C. elegans treated with 6.25 µM, 12.5 µM and 25 µM of UM-C162 
compared to untreated control (0 µM). UM-C162 at all concentrations tested confers significant enhanced 
survival in infected nematodes (p < 0.0001). (c) UM-C162 does not alter the basal lifespan of worms fed on heat 
killed E. coli OP50. Graphs in (b) and (c) show the mean ± SD of six technical replicates (20 worms/replicate) 
from a representative of two independent experiments.
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the biofilm produced by Gram-positive bacteria such as S. aureus and S. epidermidis35. A reduction in the synthe-
sis of these components is indicative of low biofilm extracellular polymeric substance production. From the anal-
ysis of the microarray data, we also noted reduced expression of ATP-dependent Clp proteases, clpB (−9.54-fold), 
clpC (−5.23-fold) (Table 2) and clpL (−2.64-fold) (Table S2). Inactivation of clpC in an S. aureus mutant decreased 
biofilm formation, proposing that ClpC is required for biofilm formation36. ClpC was also reported to affect S. 
aureus capsule production37. Furthermore, ClpB and ClpC, and to a minor extent ClpL, are required for bacterial 
long-term survival and intracellular multiplication in a cell-culture based assay36. However, we also noted that 
the expression of ctsR, a negative regulator of clp expression38, was repressed (−8.61-fold) in UM-C162-treated 
samples. Hence, clp expression may be regulated by more than one regulator or pathway.
Figure 5. Transcriptome dynamics of UM-C162-treated and untreated S. aureus. (a) Hierarchically clustered 
expression profile (rows) for 456 S. aureus genes differentially expressed upon exposure to UM-C162 as 
compared to the untreated control. Data from three independent experiments (columns) are shown. (b) 
Volcano plot showing the gene level analysis to select differentially expressed genes after treatment with 
UM-C162. The data for all genes are plotted as fold change versus −log10 of the adjusted p-value. Green, grey 
and red correspond to genes with < −2-fold, −2 to 2 fold and > 2-fold differential expression, respectively. 
(c) Verification of microarray data by qRT-PCR. Transcript levels of twelve differentially expressed S. aureus 
genes from qRT-PCR and microarray derived data were compared. Results displayed are the average relative 
fold-change for transcripts from UM-C162-treated bacteria compared to untreated control. The relative 
quantification of S. aureus RNA was determined by the change in expression of genes of interest normalized to 
S. aureus 16 s rRNA housekeeping gene.
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UM-C162 diminishes the production of key virulence factors in S. aureus. Biofilm has been recog-
nized as a major bacterial virulence factor. The components that contribute to the formation of biofilm, for exam-
ple, clf, eno, clp and cap are also classified as important virulence factors for S. aureus. ClfA mediates attachment 
to plasma clots and platelets whilst ClfB enhances clumping of cells in the presence of fibrinogen39. We noted that 
both clfA and clfB transcript levels in UM-C162 treated S. aureus were reduced relative to the untreated bacteria. 
To validate the ability of UM-C162 to inhibit S. aureus clumping factors, we assessed bacterial cell clumping activ-
ity using the slide coagulation test with rabbit plasma. Scores from 0 to 3 + were assigned based on the ability of S. 
aureus cells to form macroscopic clumps on the slides (Fig. S5). In the absence of UM-C162, S. aureus consistently 
agglutinated in rabbit plasma, whereas in bacteria-treated with UM-C162, less clumping activity was observed 
(p < 0.05) (Fig. 7a). The aggregates or clumps formed on the slides decreased with increasing concentration of 
UM-C162 and treatment with 25 µM UM-C162 completely abolished the clumping activity of S. aureus (Fig. 7a).
S. aureus produces a series of hemolysins including γ-hemolysin which lyse rabbit erythrocytes and various 
leukocytes such as neutrophils, monocytes, granulocytes and macrophages40. γ-hemolysin corresponds to two 
functional bi-component pore-forming toxins, HlgAB and HlgCB, which share the common HlgB protein. From 
the transcription profile, there is a significant decrease in the expression of genes encoding the bi-component 
γ-hemolysins (hlgA (−3.63 fold), hlgB (−4.52 fold) and hlgC (−6.61 fold)) (Table 3) in UM-C162-treated 
bacteria when compared to untreated bacteria. The hlb gene encoding ß-hemolysin or phospholipase C and 
SAOUHSC_02708, a putative leukocidin, were also down-regulated in UM-C162-treated S. aureus whilst the 
α-toxin (hla) was not significantly modulated by UM-C162. To validate the suppression of S. aureus hemoly-
sin production by UM-C162, rabbit erythrocytes were exposed to UM-C162 treated bacteria. We noted that 
UM-C162 treated S. aureus exhibited weak hemolytic activity (Fig. 7b). Up to 70% inhibition in hemolytic activity 
was noted upon treatment with UM-C162 from as low as 6.25 µM (p < 0.01) (Fig. 7b), confirming a disruption 
in hemolysin production by S. aureus. Treatment with UM-C162 at 12.5 µM and 25 µM led to a greater degree of 
hemolysis inhibition of 80% and 92% inhibition respectively.
In addition to ATP-dependent Clp proteases (Table 2), expression of sspA encoding a V8 serine protease, was 
also reduced in UM-C162-treated samples as compared to untreated bacteria (Table 3). Clp proteases direct cel-
lular functions through proteolysis of proteins such as casein and albumin, in the presence of ATP. In S. aureus, 
virulence of clp mutants is impaired in animal infection models36, suggesting that Clp proteases are crucial for 
normal cellular physiology as well as the control of the pathogen virulence machinery. V8 protease is thought to 
facilitate host tissue invasion as well as nutrient acquisition. The importance of S. aureus V8 protease for bacterial 
survival and virulence in vivo has been revealed in a number of animal infection models41. To assess the effect of 
UM-C162 on the production of S. aureus proteases, we performed the skim milk agar-based protease assay for 
both treated and untreated bacterial cultures. In the absence of UM-C162, S. aureus proteases hydrolyzed the milk 
casein resulting in the formation of a clear zone around the bacterial colony (Fig. 7c). When the bacteria were 
grown in the presence of various concentrations of UM-C162, no halo formation was evident (Fig. 7c), proposing 
that UM-C162 prevented the secretion of proteases by S. aureus.
Figure 6. Functional classification of S. aureus genes significantly modulated by UM-C162. Genes were divided 
into their respective functional groups based on clusters of orthologous groups (COGs) designations. The red 
bars correspond to induced genes while green bars show the repressed genes when S. aureus was cultured in the 
presence of 6.25 µM UM-C162.The number at the end of each bar represents the total number of genes in each 
functional class.
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In addition to hemolysins, proteases, clumping factors and the virulence factors involved in biofilm forma-
tion, treatment with UM-C162 also resulted in reduced expression of other virulence-related genes, including 
staphylococcal superantigen-like (SSL) proteins (SAOUHSC_00383, SAOUHSC_00386 and SAOUHSC_01127), 
immunoglobulin-binding protein (sbi), S. aureus surface protein A (sasA) and S. aureus exoprotein expression 
protein (saeR) (Table 3). Taken together, these biochemical tests validate the proposal that UM-C162 is a promis-
ing anti-biofilm and anti-virulence agent towards S. aureus.
Discussion
S. aureus is a key etiological agent responsible for infections that impose substantial financial burden on hospitals 
globally as well as high mortality and morbidity rates. The alarming increase in antibiotic-resistant S. aureus 
advocates the need to search for novel anti-infective drugs. In this study, we screened a collection of 35 benzimi-
dazole derivatives for potential anti-infective activity towards S. aureus16. From this screen, we identified 12 pos-
itive hits of which three are able to alleviate S. aureus biofilm formation. Previously, a similar screen successfully 
identified a number extracts and compounds with anti-bacterial effects16. In addition, a plant extract that did 
not affect bacterial growth was able to stimulate the host antimicrobial response to clear the infection42. Hence, 
it is possible that some of the positive hits may permit increased survival of infected hosts by inhibiting bacterial 
growth or activating the host immune response to eradicate the bacteria. Benzimidazoles are widely used as 
anti-helminthics to treat nematode and trematode infections in domestic animals43. In our study, we also noted a 
small number of benzamidazole derivatives that killed C. elegans even in the absence of infection supporting the 
advantage of this C. elegans screen in facilitating the elimination of compounds that are toxic to the host.
Rapid developments and advances in structure-based rational design of novel molecular entities that function 
or target certain biomolecular pathways have led to the discovery of potential therapies for infectious diseases. 
The collection of benzimidazole derivatives used in this study have previously been tested for their inhibitory 
effect on poly (ADP-ribose) polymerase-1 (PARP-1) and dihydroorotate dehydrogenase (DHODH) and a num-
ber of these compounds showed promising anti-PARP-1 and DHODH effects, suggesting their prospective role 
in anti-cancer therapy44. Of note, two positive hits in our anti-infective screen, UM-C49 and UM-C201, were also 
able to inhibit both PARP-1 and DHODH enzymes. UM-C162 demonstrated modest DHODH inhibition and a 
compound with a similar structure (UM-C187) showed dual potency on both DHODH and PARP-144. Recently, 
several other compounds that exhibit both anti-cancer and anti-biofilm effects in vitro have been discovered45,46. 
Nevertheless, the link between anti-cancer and anti-biofilm activities is yet to be clarified.
An anti-infective agent that reduces bacterial virulence without disrupting bacterial viability is thought to 
avoid the selective pressure that promotes antibiotic resistance5. Benzimidazole derivatives with potent antimi-
crobial activity against both bacteria and fungus have previously been reported15. Conversely, in our study, both 
the antimicrobial test (Fig. S4) and growth curve analysis (Fig. 4a) demonstrated that UM-C162 was not antibac-
terial towards S. aureus, advocating the potential of UM-C162 as an anti-virulence candidate that is not likely to 
stimulate bacterial resistance. Furthermore, an anti-virulence agent that does not impede bacterial growth is not 
likely to interfere with the preservation of host endogenous flora.
Previously, a benzimidazole analog, 5-methoxy-2-[(4-methylbenzyl)sulfanyl]-1H-benzimidazole (also known 
as ABC-1), was identified as a wide-spectrum biofilm inhibitor towards both Gram-positive and Gram-negative 
bacterial biofilm (including S. aureus, MRSA, Vibrio cholerae, Pseudomonas aeruginosa) without having 
any impact on bacterial growth18. At 25 µM, ABC-1 inhibited S. aureus biofilm by < 50% whilst in this study, 
UM-C162 was able to inhibit S. aureus biofilm by > 50% even at 6.25 µM. In addition, the 2-aminobenzimidazole 
class of compounds also exhibits biofilm inhibitory effects45, proposing that compounds containing a benzimida-
zole functional group are a promising scaffold for the discovery of novel anti-biofilm candidates.
The diversity and functional redundancy of S. aureus virulence factors is important to the overall fitness and 
disease causation of S. aureus in the host. As a result, attenuating a single virulence factor does not usually lead 
to the diminution of S. aureus virulence. Our genome-wide transcriptome profile and SEM analysis indicate that 
Function
No. of 
genes Genes P value
Up-regulated
Translation 30
SAOUHSC_02504, SAOUHSC_01666, rpsC, rpsD, rpsE, rpsH, rpsJ, rpsQ, 
rpsS, rpsT, rplB, rplC, rplD, rplE, rplF, rplJ, rplN, rplP, rplQ, rplR, rplT, 
rplV, rplW, rplX, rpmA, rpmC, rpmD, def, pheT, thrS,
p < 0.0001
ABC transporter/permease protein 8
SAOUHSC_00074, SAOUHSC_00136, SAOUHSC_00169, 




Cell wall/external encapsulating structure 23
SAOUHSC_00114, SAOUHSC_00356, SAOUHSC_00383, 
SAOUHSC_00386, SAOUHSC_00437, SAOUHSC_01127, 
SAOUHSC_02549, SAOUHSC_02708, SAOUHSC_02971, capF, capL, 
capA, clfA, clfB, eno, hlgB, hlgC, sspA, sbi, hlb, sasA, sdrC, atl
p < 0.0001
Pathogenesis/virulence 19
SAOUHSC_00383, SAOUHSC_00386, SAOUHSC_01127, 
SAOUHSC_02708, clfA, clfB, eno, hlgB, hlgC, hlb, sspA, sbi, sasA, sdrC, 
saeR, yent1, arlS, clpL, clpC
p < 0.0001
Response to stress/DNA repair 9 SAOUHSC_00503, SAOUHSC_01363, SAOUHSC_01667, clpC, clpL, recO, recF, recA, recN p < 0.01
Table 1. Functional enrichment of S. aureus genes induced and suppressed by UM-C162.
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UM-C162 most likely blocks S. aureus adherence or cell aggregation, which is the first step in the process of bio-
film production. A cohort of virulence factor-encoding genes was suppressed in UM-C162-treated bacteria but 
not in the untreated control. Together with the outcomes from the biochemical assays, we provide evidence that 
compound UM-C162 inhibits the production of several S. aureus virulence factors, namely biofilm, clumping 
factors, hemolysins and proteases. These surface proteins, toxins and enzymes are vital for the pathogen to attach 
to host cells, establish an infection, impair the host immune reaction and result in host tissue deterioration. A 
previous S. aureus - C. elegans host-pathogen interaction study revealed that the virulence determinants, includ-
ing hemolysins, V8 serine proteases and biofilm, are needed for full pathogenicity of S. aureus in the nematode 
model of infection17,47. S. aureus mutants for these crucial virulence factors were attenuated in C. elegans killing47. 
By blocking these virulence traits, the bacteria are rendered less virulent and less able to disseminate within the 
host. This allows the host immune response to initiate elimination of the less pathogenic bacteria from the host, 
ensuring the survival of the infected host.
A complex process of multiple systems is required to regulate the expression of virulence-associated genes. 
Among the well-studied regulators are the two component systems Agr operon, SaeRS, ArlSR and SarA global 
transcriptional regulators4. We noted a down-regulation of the transcript levels for saeR and arlS while the expres-
sion of agr and sarA remained unchanged upon treatment with UM-C162, suggesting that UM-C162 might target 
the regulator/s upstream of saeRS and arlSR. SaeRS and ArlSR regulate the expression of genes encoding S. aureus 
virulence factors such as hemolysins, coagulases, lipase and S. aureus surface protein A48,49. Through various 
biochemical assays, we consistently observed suppression of hemolysins, coagulases and proteases by UM-C162.
S. aureus biofilms are often associated with chronic infections and contaminated implanted medical devices 
and the presence of biofilm renders the bacteria highly tolerant to antibiotics and able to resist phagocytosis. 
Additionally, S. aureus expresses an arsenal of virulence determinants that contribute to its versatility in surviving 
the host defence response. In our search for novel anti-infectives that target bacterial virulence, we identified a 
benzimidazole-based molecule, UM-C162, as a potential anti-virulence agent that interferes with the production 
of bacterial virulence determinants (e.g. toxins, enzymes and biofilm). In light of its ability to inhibit a myr-
iad of key S. aureus virulence factors, UM-C162 is a promising anti-virulence agent to be further developed 
as an anti-infective agent. No detectable toxic effect on adult worms was observed signifying that UM-C162 is 
non-toxic to the eukaryotic host. Our results strongly propose UM-C162 as a potential anti-virulence candidate 
with minimal toxicity, to be developed as an alternative therapeutic for S. aureus infections.
Methods
Bacteria and nematode growth conditions. S. aureus strains used were NCTC8325-4, ATCC25923 
and a MRSA clinical strain22 (Adelaide Pathology Partners (Mile End, Australia)). S. aureus NCTC8325-4 was 
used in all experiments unless otherwise specified. S. aureus was routinely grown in Trypticase Soy (TS) media 
(Oxoid/Pronadisa) and incubated at 37 °C under aerobic conditions. A uracil-requiring strain of Escherichia coli 
OP50 was propagated on Luria-Bertani (LB) media (Pronadisa) with streptomycin (100 µg/mL) at 37 °C. The wild 
type C. elegans N2 strain was cultivated on nematode growth medium (NGM) with E. coli OP50 as their food. 
The nematodes were rendered sterile by RNAi knockdown of the pos-1 gene that caused the gravid worms to lay 
unhatched eggs50. This eliminates any confusion in the scoring as a result of nematode reproduction. The pos-1 
RNAi treated nematodes were allowed to develop into young adult worms to be used in the screen.
Role in biofilm formation Genes Fold change (UM-C162-treated vs control)

















Surface protein of Gram positive cocci
SAOUHSC_00437 −3.69
SAOUHSC_02549 −2.75
Teichoic acid biosynthesis protein
SAOUHSC_00974 −25.4
SAOUHSC_00643 −2.6
Peptidoglycan biosynthesis SAOUHSC_01987 −2.12
Table 2. Suppression of known S. aureus genes associated with biofilm formation.
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Figure 7. Effect of UM-C162 on S. aureus virulence factors. (a) Results of S. aureus slide clumping factor 
assay. Shown are the pictures of S. aureus cell clumping in rabbit plasma in the presence and absence of UM-
C162. Cultures supplemented with UM-C162 at 6.25 µM and 12.5 µM demonstrate weak agglutination with 
turbid background while cells treated with 25 µM show no cell agglutination. Bars represent the mean ± SD of 
clumping scores (expressed in arbitrary units) corresponding to the formation of bacteria cell clumps (n = 5 
for each treatment) according to the criteria presented in Fig. S5. (b) Anti-hemolytic property of UM-C162 
against S. aureus. Hemolysis of red blood cells by S. aureus in the presence of UM-C162 at 6.25 µM, 12.5 µM and 
25 µM was measured following 4 hours incubation at 37 °C. Treatment with UM-C162 at various concentrations 
dramatically reduces the ability of S. aureus to lyse red blood cells. Pictures of spectrophotometer cuvettes 
indicating hemolytic activity of S. aureus are shown. (c) Effect of UM-C162 on the production of S. aureus 
proteases. Shown are the representative micrographs of halo formation (indicated by black arrow) in untreated 
S. aureus culture (0 µM) and absence of halo formation in UM-C162-treated bacteria on 3% skim milk agar after 
24 hours incubation. (*) marks significant difference between untreated (0 µM) and UM-C162-treated bacteria 









Phospholipase C hlb −2.31
Serine protease (V8 protease) sspA −2.07




Immunoglobulin-binding protein sbi −3.09
S. aureus surface protein A sasA −2.84
S. aureus exoprotein expression protein saeR −2.9
Table 3. Down-regulation of S. aureus genes encoding major virulence factors.
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Synthesis and preparation of benzimidazole derivatives. Thirty five compounds with the benzimi-
dazole backbone were synthesized using the previously described procedures44 as outlined in the scheme in Fig. 8. 
Briefly, various functional groups were placed at the R3, R4 and R5 positions of the corresponding carboxylic acid 
intermediates by de novo synthesis. Two different routes were employed to prepare the compounds. The first 
route (for R1 = OCH3) involves coupling of diamine a with carboxylic acid b by using 1-[bis(dimethylamino) 
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxidhexafluoro-phosphate (HATU). Subsequent thermal 
cyclization of the resulting amide c in acetic acid gave benzimidazole ester d. Saponification of the ester d with 
lithium hydroxide resulted in the benzimidazole carboxylic acids e which were then converted to the corre-
sponding benzimidazole carboxamide f with 1-hydroxybentzotriazole (HOBt). The second route (for R1 = NH2) 
involves direct coupling of diamine a with carboxylic acid b in the presence of 1,1′-carbonyldiimidazole (CDI). 
Subsequent thermal cyclization of the resulting amide c in one-pot afforded benzimidazole carboxamide f in 
two-steps. DMSO was used as the solvent and all reconstituted compounds were filter sterilized using a 0.2 µm 
membrane and stored at −20 °C before use.
C. elegans – S. aureus anti-infective screen. Screening for potential anti-infective agents was performed 
as previously described16. Briefly, medium containing worm M9 buffer, S. aureus culture and 10 µg/mL choles-
terol was prepared and added into individual wells in a 48-well plate. Each benzimidazole derivative was indi-
vidually added to a final concentration of 100 µM. The controls were prepared by replacing the compound with 
DMSO (untreated control) or by replacing S. aureus with E. coli OP50 (uninfected control). Ten age-matched 
pos-1 treated nematodes were manually transferred into the liquid medium and the plate was incubated at 25 °C 
without agitation. The number of live and dead worms was scored every 24 hours. Positive hits were selected 
based on ≥70% survival of S. aureus-infected compound-treated worms in at least two replicates at a point when 
~20% of the untreated control worms survived.
Antimicrobial tests. To determine the antimicrobial activity of benzimidazole compounds, the broth 
microdilution test and bacterial growth analysis were performed. S. aureus was cultured in 3 mL of TS broth and 
incubated overnight (16–18 hours) at 37 °C in a shaking incubator. The initial bacterial inoculum size was stand-
ardized by diluting the S. aureus overnight culture to OD600 = 0.3. The bacterial suspension was further diluted 
1:100 to obtain 106 cfu/mL. To determine the minimum inhibitory concentration (MIC), a series of different 
concentrations of compound was prepared by two-fold serial dilution in a 96-well plate, followed by inoculation 
with 106 cfu/mL S. aureus and overnight incubation at 37 °C. Gentamicin (0.03 mg/mL to 50 mg/mL) and DMSO 
(0.0005% to 1%) served as the positive and negative controls, respectively. To evaluate the effect of compound 
UM-C162 on S. aureus growth, a standardized suspension of 108 cfu/mL S. aureus was diluted (1:100) in TS broth 
supplemented with the compound at different concentrations, followed by incubation at 37 °C with shaking. At 
selected time intervals, the turbidity of the culture was measured at 600 nm.
Crystal-violet biofilm assay. The biofilm assay was conducted in a 96-well polystyrene flat-bottomed 
microplate (Greiner Bio-One). Firstly, the standardized S. aureus suspension at 106 cfu/mL was prepared and 
dispensed into each well in the 96-well plate. To screen for anti-biofilm activity, individual benzimidazole com-
pounds were added to the bacterial suspension to a final concentration of 100 µM and tested in duplicate wells, 
representing two technical replicates. For the dose-dependent anti-biofilm assay, the selected compound was 
tested across of series of concentrations, ranging from 100 to 0.78 µM. As a control, the compound was replaced 
with DMSO. Uninoculated TS broth was also included as the blank control. The plate was incubated at 37 °C for 
24 hours under static conditions. After incubation, the wells were washed three times with 1X phosphate buffered 
saline (PBS) to eliminate non-adherent bacteria and fixed with 99% (v/v) methanol for 15 minutes. The wells 
were allowed to dry in a laminar flow. The attached biofilm cells were stained using filtered 0.5% crystal violet 
(Sigma-Aldrich) for 5 minutes at room temperature. The excess stain was removed by rinsing with water and 
crystal violet bound cells were solubilised with 33% acetic acid. The released stain was measured at 570 nm using 
a microplate reader (Sunrise, Tecan). Analysis was performed on three independent occasions and two technical 
replicates for each compound.
Scanning electron microscopy (SEM) analysis of biofilm formation. An overnight culture of 
S. aureus was adjusted to OD600 = 0.3 and further diluted 1:100 in TS broth to obtain 106 cfu/mL S. aureus. 
UM-C162 was tested at 6.25 µM, 12.5 µM and 25 µM. For each concentration, 4 mL of bacterial suspension was 
supplemented with the desired amount of compound and added into individual wells in a 6-well plate. A glass 
Figure 8. General synthesis of benzimidazole derivatives. Reaction conditions: For R1 = OCH3 (i) HATU, 
DIPEA, DMF (ii) AcOH, 110 °C (iii) LiOH, MeOH/THF (iv) HOBt, EDCl, NH4Cl, DIPEA, DMF; For R1 = NH2 
(i) CDI, pyridine, DMF (ii) AcOH, 110 °C.
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slide (about 10 mm × 10 mm) was positioned in the middle of each well. The plate was incubated at 37 °C for 
24 hours to allow the formation of biofilm on the slides. The bacteria cells were processed for SEM as described 
previously51. Briefly, the samples were fixed overnight at 4 °C in 4% (v/v) glutaraldehyde, rinsed three times with 
1X PBS and dehydrated through a graded ethanol series (35%, 50% and 70%), followed by critical-point drying 
in a drying apparatus with liquid CO2. The samples were gold-coated using a gold sputtering unit and observed 
using a LEO 1450VP variable pressure scanning electron microscope (Electron Microscopy Unit, Universiti 
Kebangsaan Malaysia).
Artificial dermis wound biofilm model. An artificial dermis was prepared as previously described22. The 
dermis consisting of hyaluronic acid and collagen spongy sheets was sterilized by UV light treatment followed by 
heating at 110 °C for an hour before use. A mixture of lyophilized bovine plasma, Bolton broth, horse blood and 
heparin was prepared and added to the dermis in a 24-well plate. Overnight cultures of S. aureus ATCC 25923 
and a clinical strain of MRSA was adjusted to 1 × 106 cfu/mL and 10 µL of adjusted bacterial inoculum was inoc-
ulated onto the surface of each dermis. To assess for a potential biofilm inhibitory effect, UM-C162 was added 
to each artificial dermis immediately after the dermis was inoculated with bacteria. On the other hand, to assess 
for the eradication of biofilm, following bacterial inoculation, biofilm was allowed to form on the dermis at 37 °C 
for 24 hours. After the formation of biofilm on each dermis, sterile filter paper impregnated with UM-C162 was 
placed in contact with the biofilm, followed by incubation at 37 °C for 24 hours. The dermis was transferred to 
10 mL saline and biofilm was extracted by vortexing and sonication. Recovered bacterial cells were serially diluted 
and plated on TSA supplemented with 7.5% NaCl. Plates were incubated overnight at 37 °C and colonies were 
counted. All experiments were repeated twice independently with at least two technical replicates.
Nematode survival and lifespan assays. C. elegans survival and lifespan assays were conducted to exam-
ine the effect of benzimidazole compounds in a live-animal model as previously described16,42. The survival assay 
was performed to confirm the anti-infective effect of the selected benzimidazole compound, UM-C162, at dif-
ferent concentrations whilst the lifespan assay was performed to assess potential toxicity on uninfected worms. 
These assays were performed using a liquid-based medium in the same manner as the anti-infective screen except 
the number of worms used was increased from ten to twenty worms per well and six technical replicates were 
analysed. The lifespan assessment experiment was conducted by feeding the worms with heat-killed E. coli OP50 
in the presence of UM-C162. Heat-killed (65 °C for 30 minutes) E. coli OP50 were used to avoid any possible effect 
of UM-C162 on the bacteria which may contribute to a reduction in C. elegans lifespan. The bacteria were added 
into M9 medium supplemented with different concentrations of compound before transferring age-matched 
pos-1 RNAi treated nematodes into the medium. The plates were kept at 25 °C. Survival of treated and untreated 
worms was monitored over time until all worms died. The experiment was performed in duplicate.
Total RNA extraction. Total bacterial RNA was extracted using MasterPureTM Complete DNA and RNA 
Purification Kit (Epicentre) with minor modifications. In brief, S. aureus was cultured for 16–18 hours in the pres-
ence and absence of UM-C162 (6.25 µM) at 37 °C with agitation. The bacterial culture was centrifuged at 8000 × g 
for 1 minute to pellet the cells which were then resuspended in 150 µL of TE buffer (Epicentre MasterPureTM 
Complete DNA and RNA Purification Kit). Lysozyme (15 µL) (Sigma-Aldrich) was added to a final concentra-
tion of 2.5 mg/mL and the mixture was incubated at 37 °C for 30 minutes. Ten µL of Proteinase K (Qiagen) was 
diluted in 150 µL of Tissue & Cell Lysis Solution and added to the samples, followed by incubation at 65 °C for 
15 minutes in a water bath. After incubation, the samples were left to equilibrate to room temperature and placed 
on ice for 3 minutes. Removal of contaminating DNA was done according to Epicentre protocols. Total RNA was 
further purified with the Qiagen RNeasy Mini Kit and residual DNA was completely removed using the Qiagen 
RNase-Free DNase Set according to the manufacturer’s instructions. The presence of DNA contamination in 
the RNA samples was assessed by PCR targeting the nuc gene using primers and PCR protocol as previously 
described52. The quantity and quality of RNA was measured with the NanoDrop 2000C spectrophotometer and 
RIN number was analyszed using the Agilent 2100 Bioanalyser.
Microarray gene expression profiling and data analysis. RNA samples were processed according 
to the Affymetrix SensationPlus FFPE Amplification and 3′IVT Labeling Kit protocol. Briefly, 50 ng of total 
RNA was reversed transcribed to produce cDNA/mRNA hybrid molecules, which were subsequently used as 
template to produce sense RNA via in vitro transcription (IVT). IVT-generated sense RNA was purified, sub-
jected to single-stranded cDNA synthesis following which the cDNA was fragmented, end-labelled and hybrid-
ized to the Affymetrix GeneChip S. aureus Genome Array (Affymetrix, Cat. No. 900514) for 16 hours at 45 °C 
with rotation at 60 rpm. Following hybridization, arrays were washed and stained using the FS450_0005 fluidics 
protocol and scanned using an Affymetrix 3000 7 G scanner. The scanned images were inspected for hybridiza-
tion efficiency. To perform data quality control (QC), feature intensity (CEL) files generated from GeneChip® 
Command Console® Software (AGCC) were imported into the Affymetrix Expression Console (EC) 1.4 soft-
ware. MAS5 algorithm was used for normalizing probe-level intensity. QC metrics were generated and extracted 
from the Affymetrix EC report. Raw data were submitted to the Affymetrix EC software to generate probe set 
summarization (CHP) files from CEL files using the PLIER algorithm. Gene expression analysis was performed 
using three independent mRNA samples for each group. To perform statistical analysis and identify the dif-
ferentially expressed genes, the resultant data (CHP files) were submitted to the Affymetrix® Transcriptome 
Analysis Console (TAC) software for Gene Level Differential Expression Analysis. Genes with a p value < 0.05 
and threshold values of ≥ 2 and ≤ – 2-fold change between the UM-C162-treated samples and the untreated con-
trols were defined as significantly differentially expressed. The complete microarray dataset has been deposited 
in NCBI’s GEO database and can be accessed through GEO accession number GSE84485 (http://www.ncbi.nlm.
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nih.gov/geo/query/acc.cgi?acc=GSE84485). Functional classifications were carried out based on clusters of ort-
hologous groups (COGs) designations for S. aureus NCTC8325 (http://www.ncbi.nlm.nih.gov/COG/). Gene 
function enrichment analysis was performed against the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) Bioinformatics Resources version 6.7 (https://david.ncifcrf.gov/) using Fisher Exact test with 
Benjamini-Hochberg multiple testing correction (p < 0.05).
Quantitative RT-PCR (qRT-PCR) analysis. qRT-PCRs on total DNA-free RNA using the iTaqTM 
Universal One-Step RT-qPCR kits with SYBR Green (BioRad Laboratories, USA) were performed according 
to the manufacturer’s recommendations on the Bio-Rad CFX96 Touch Real-Time PCR Detection System. The 
parameters for the RT-PCR cycle used were 50 °C for 30 minutes, 95 °C for 5 minutes, 95 °C for 30 seconds, 60 °C 
for 30 seconds, 76 °C for 30 seconds and 60 °C for 7 minutes. Amplification specificity was confirmed by melt 
curve analysis where the reaction temperature was increased from 55 °C to 95 °C over 10 seconds (0.5 °C incre-
ment for 80 cycles) after amplification. The forward and reverse primers used are listed in Table S3. The average 
cycle threshold (Ct) values were normalized against the S. aureus 16 s rRNA53 that was found to not vary upon 
treatment. The mRNA expression levels of genes of interest was computed using the CFX ManagerTM software 
(Bio-Rad Laboratories, USA) on the average normalized Ct value.
Analysis of virulence factors production. Plasma clumping factor test. S. aureus was cultured over-
night at 37 °C in the presence and absence of UM-C162. Bacterial cells harvested from the overnight culture were 
prepared in 1X PBS. Rabbit blood plasma was separated from red blood cells by centrifugation at 900 × g for 
5 minutes. Twenty µL of rabbit plasma was placed on the surface of a glass slide, followed by inoculation of 10 µL 
of S. aureus suspension. The mixture was mixed evenly for 10 seconds and macroscopic clumping/agglutination 
of bacterial cells was scored from 0 to 3+ (Fig. S5).
Haemolysin test. Lysis of red blood cells was assessed as previously described9 with minor modifications. Briefly, 
different concentrations of UM-C162 were added to a S. aureus culture with standardized inoculum size, followed 
by incubation at 37 °C with agitation for 16–18 hours. Rabbit blood was obtained from the Animal House Facility, 
Universiti Kebangsaan Malaysia. Red blood cells were separated from plasma by centrifugation at 900 × g for 
5 minutes at 4 °C, washed 3 times with 1XPBS and diluted in PBS (330 µL of red blood cells in 10 mL of 1X PBS). 
To measure the haemolytic activity, 200 µL of S. aureus culture (OD600 = 0.3) grown in the presence of compound 
was added into 10 mL of diluted red blood cells. The negative control (S. aureus supplemented with DMSO only) 
was run in parallel. The mixture was incubated shaking for 4 hours. Supernatants were collected by centrifugation 
at 16,600 × g for 10 minutes and the OD readings were measured at 543 nm.
Protease test. The ability of UM-C162-treated and untreated S. aureus to produce protease was determined 
by spotting the bacterial culture on 3% skim milk agar (Oxoid, UK). S. aureus was grown overnight at 37 °C in 
the presence and absence of compound and adjusted to the standard inoculum size. Ten µL of standardized S. 
aureus inoculum was spotted onto skim milk agar, allowed to dry under sterile conditions and incubated at 37 °C 
for 24 hours. After 24 hours incubation, plates were observed for the formation of a clear zone/halo around the 
bacteria.
Statistical analysis. At least three replicates were performed for the purpose of statistical analysis unless 
otherwise specified. For assays involving enumeration of dead and live worms, the worms were defined as dead 
when no response was detected upon picker touch and no pumping was observed at the pharynx. Dead worms 
with protruding vulvas were excluded from the analysis. Data from survival assays were analysed using the 
Kaplan-Meier nonparametric analysis in the StatView® 5.0.1 software (SAS Institute, Inc.). The pair wise com-
parison was analysed using the Log-rank (Mantel-Cox) significance test. For selection of significantly differen-
tially expressed genes in the microarray analysis, a One-Way Between-Subject Analysis of Variance (ANOVA) 
(unpaired) was performed for treated and untreated groups. The data from other experiments were expressed as 
mean ± standard error of mean from at least two independent assays or mean ± standard deviation from one rep-
resentative replicate. Statistical analyses for the biofilm assays and hemolysin test were performed using Student’s 
t-test. The ordinal data from the clumping factor assay were analyzed with the Mann-Whitney U-test.
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